Synergy Pharmaceuticals Inc (SGYP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Synergy Pharmaceuticals Inc (SGYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9812
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Synergy Pharmaceuticals Inc (Synergy Pharma) is a biopharmaceutical company that develops and commercializes new treatments for gastrointestinal (GI) diseases. The company pioneered its R&D efforts to develop its proprietary uroguanylin-based GI platform. It is also developing analogs of uroguanylin, a naturally occurring human GI peptide that promotes normal bowel function. The company’s portfolio includes Trulance (plecanatide), which is structurally identical to uroguanylin, for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. Synergy Pharma’s pipeline includes dolcanatide (SP-333), an investigational candidate under evaluation for the treatment of OIC and UC. Synergy Pharma is headquartered in New York, the US.

Synergy Pharmaceuticals Inc (SGYP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 12
Partnerships 13
Bind Therapeutics and Synergy Pharma Enter into Research Agreement 13
Licensing Agreements 14
Shandong Luoxin Pharma Enters into Licensing Agreement with Synergy Pharma 14
Cipher Pharma Enters into Licensing Agreement with Synergy Pharma 15
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 16
Equity Offering 17
Synergy Pharma Prices Public Offering of Shares for USD56 Million 17
Synergy Pharma Raises USD125 Million in Public Offering of Shares 19
Synergy Pharma Plans to Raise Funds in Public Offering of Shares 20
Synergy Pharma Raises USD89.8 Million in Private Placement of Shares 21
Synergy Pharma Announces Public Offering Of Shares For Up To US$50 Million 22
ContraVir Pharma Spin Off from Synergy Pharma 23
Synergy Pharma Completes Public Offering Of Shares For US$90 Million 24
Synergy Pharma Completes Exercise Of Underwriters’ Option For Public Offering Of Shares For US$51.75 Million 26
Debt Offering 28
Synergy Pharma Raises USD79.8 Million in Private Placement of Notes Due 2019 28
Synergy Pharma Raises USD200 Million in Private Placement of 7.5% Notes Due 2019 29
Acquisition 31
Synergy Pharma Completes Acquisition Of Callisto Pharma 31
Synergy Pharmaceuticals Inc – Key Competitors 32
Synergy Pharmaceuticals Inc – Key Employees 33
Synergy Pharmaceuticals Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Aug 07, 2018: Synergy Pharmaceuticals reports second quarter 2018 financial results and business update 35
May 10, 2018: Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update 37
Mar 01, 2018: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update 39
Nov 09, 2017: Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results 40
Aug 09, 2017: Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update 41
May 10, 2017: Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update 43
Mar 01, 2017: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update 45
Corporate Communications 47
Oct 31, 2018: Synergy Pharmaceuticals names Dr. Melvin K. Spigelman Chairman 47
Apr 17, 2017: Synergy Pharmaceuticals Appoints Gary G. Gemignani as Chief Financial Officer 48
Other Significant Developments 49
Oct 17, 2017: Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with Irritable Bowel Syndrome with Constipation (IBS-C) 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synergy Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 12
Bind Therapeutics and Synergy Pharma Enter into Research Agreement 13
Shandong Luoxin Pharma Enters into Licensing Agreement with Synergy Pharma 14
Cipher Pharma Enters into Licensing Agreement with Synergy Pharma 15
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 16
Synergy Pharma Prices Public Offering of Shares for USD56 Million 17
Synergy Pharma Raises USD125 Million in Public Offering of Shares 19
Synergy Pharma Plans to Raise Funds in Public Offering of Shares 20
Synergy Pharma Raises USD89.8 Million in Private Placement of Shares 21
Synergy Pharma Announces Public Offering Of Shares For Up To US$50 Million 22
ContraVir Pharma Spin Off from Synergy Pharma 23
Synergy Pharma Completes Public Offering Of Shares For US$90 Million 24
Synergy Pharma Completes Exercise Of Underwriters' Option For Public Offering Of Shares For US$51.75 Million 26
Synergy Pharma Raises USD79.8 Million in Private Placement of Notes Due 2019 28
Synergy Pharma Raises USD200 Million in Private Placement of 7.5% Notes Due 2019 29
Synergy Pharma Completes Acquisition Of Callisto Pharma 31
Synergy Pharmaceuticals Inc, Key Competitors 32
Synergy Pharmaceuticals Inc, Key Employees 33
Synergy Pharmaceuticals Inc, Subsidiaries 34

List of Figures
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Synergy Pharmaceuticals Inc (SGYP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Niko Resources Ltd (NKO):石油・ガス:M&Aディール及び事業提携情報
    Summary Niko Resources Ltd (Niko Resources) is an independent oil and gas exploration and production company that acquires, explores, develops and produces crude oil and natural gas properties. The company concentrates on value generation in the D6 Block in India. It offers financing options for the …
  • Cummins Inc (CMI):企業の財務・戦略的SWOT分析
    Cummins Inc (CMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Energias de Portugal SA (EDP)-石油・ガス分野:企業M&A・提携分析
    Summary Energias de Portugal, S.A. (EDP) is a vertically integrated power and gas utility that generates, transmits, distributes and sells electricity; and transports, distributes and sells natural gas. It produces electricity through a diversified portfolio of generation assets including wind, sola …
  • Stellar Resources Ltd
    Stellar Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Stellar Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Beijing Beilu Pharmaceutical Co Ltd (300016):製薬・医療:M&Aディール及び事業提携情報
    Summary Beijing Beilu Pharmaceutical Co Ltd (Beijing BeiLu) is a manufacturer of traditional Chinese medicine preparation and psychiatric products. The company provides product portfolio such as contrast media products, anti anxiety medicines and oral antihyperglycemic agents, among others. Its cont …
  • Cosmo Energy Holdings Co Ltd (5021):企業の財務・戦略的SWOT分析
    Cosmo Energy Holdings Co Ltd (5021) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Charles River Laboratories International Inc (CRL):企業の財務・戦略的SWOT分析
    Charles River Laboratories International Inc (CRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Stratasys Ltd:企業の戦略・SWOT・財務情報
    Stratasys Ltd - Strategy, SWOT and Corporate Finance Report Summary Stratasys Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Absorption Systems LP-製薬・医療分野:企業M&A・提携分析
    Summary Absorption Systems LP (Absorption Systems) is a pre-clinical contract research organization that develops and implements research tools. The organization carries out preclinical testing of drugs, biologics, and medical devices. It develops and implements research tools to predict human outco …
  • Medical Australia Ltd (MLA)-医療機器分野:企業M&A・提携分析
    Summary Medical Australia Ltd (Medical Australia), formerly BMDi TUTA Healthcare is a medical device company that manufactures and delivers medical devices and equipment for the healthcare industry. The company offers products such as IV systems, safety, blood banking, surgical and anaesthesia produ …
  • iBio Inc (IBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary iBio Inc (iBio) is a biotechnology company that develops and manufactures plant made pharmaceutical products. The company provides products such as biotherapeutics and vaccines. It has its applications in ibiolaunch platform, which is a transformative technology for the production of monoclo …
  • Carnival Corporation & plc:企業の戦略・SWOT・財務情報
    Carnival Corporation & plc - Strategy, SWOT and Corporate Finance Report Summary Carnival Corporation & plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Abiomed Inc (ABMD):医療機器:M&Aディール及び事業提携情報
    Summary Abiomed Inc (Abiomed) is a provider of mechanical circulatory support devices. It develops, manufactures and markets novel technologies designed to replace or assist the pumping function in a failing heart. The company’s heart support and recovery product portfolio includes catheters for cir …
  • The Nisshin OilliO Group Ltd (2602):企業の財務・戦略的SWOT分析
    The Nisshin OilliO Group Ltd (2602) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Fugro NV (FUR):電力:M&Aディール及び事業提携情報
    Summary Fugro NV (Fugro) is an integrated provider of geotechnical, survey, subsea and geosciences services. The company specializes in earth and engineering data services, from project preparation through to data acquisition, processing, analysis and interpretation, reporting and consulting. It ass …
  • Nationwide Children’s Hospital-製薬・医療分野:企業M&A・提携分析
    Summary Nationwide Children's Hospital (Nationwide Children's) is a provider of pediatric health care and research services. The hospital offers pediatric services in the areas of gastroenterology, hematology and nutrition, heart care, left lip and palate, oncology ad bone marrow transplantation. It …
  • Zirax Ltd:企業の戦略的SWOT分析
    Zirax Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Pathway Genomics Corp:医療機器:M&Aディール及び事業提携情報
    Summary Pathway Genomics Corp (Pathway Genomics) is a healthcare laboratory that offers genetic testing services. Its tests comprise liquid biopsy cancer intercept, true hereditary cancer genetic tests, DNA insight general health and wellness genetic tests, DNA insight pharmacogenomics tests, and ca …
  • Biovotion AG:医療機器:M&Aディール及び事業提携情報
    Summary Biovotion AG (Biovotion) is a medical device company that offers healthcare monitoring solutions. The company offers Ecosystem, Everion and Augment app. Its Ecosystem is a wearable sensor monitor that consists of data collection, analytics, storage in the cloud and visualization tools used i …
  • Seikagaku Corp (4548):企業の財務・戦略的SWOT分析
    Summary Seikagaku Corp (Seikagaku) is a manufacturer and supplier of pharmaceuticals and medical devices. The company offers products such as pharmaceuticals and medical devices, bulk products, endotoxin-detecting reagents and oral care products. It also manufactures and markets pharmaceutical produ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆